Off-label use of rituximab in dermatology: pemphigus treatment
Since its approval in 1997 by the FDA (United States Food and Drug Administration), rituximab has been used for certain B-cell lymphomas and treatment-resistant rheumatoid arthritis. Nevertheless, over the past 14 years, many case reports have demonstrated the efficacy of off-label rituximab in several dermatological inflammatory conditions. This study describes two cases of pemphigus vulgaris and two cases of pemphigus foliaceous that were treated with rituximab at 375 mg/m2 once a week for 4 weeks, and that responded well to treatment.
Saved in:
Main Authors: | Bomm,Lislaine, Fracaroli,Tainá Scalfoni, Sodré,João Luz, Bressan,Aline, Gripp,Alexandre Carlos |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Sociedade Brasileira de Dermatologia
2013
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962013000400676 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus - Brazilian Society of Dermatology
by: Porro,Adriana Maria, et al.
Published: (2019) -
Refractory pemphigus vulgaris treated with rituximab and mycophenolate mofetil
by: Biot,Stephanie Del Rio Navarrete, et al.
Published: (2014) -
Toxic epidermal necrolysis induced by lansoprazole*
by: Fracaroli,Tainá Scalfoni, et al.
Published: (2013) -
Severe Multi-Resistant Pemphigus vulgaris: prolonged remission with a single cycle of Rituximab
by: Corral,Isabela Soubhia, et al.
Published: (2013) -
Uso da ciclosporina em paciente portador de hepatite C e psoríase pustulosa
by: Bomm,Lislaine, et al.
Published: (2011)